Tissue hemostasis is shifted toward thrombogenesis in the psoriatic plaques

Gębska, Edyta; Sikora, Agnieszka; Michalski, Marek; Reichman-Warmusz, Edyta; Kurek, Józef; Dudek, Damian; Skowron, Wiktor; Jarząb, Jerzy; Wojnicz, Romuald

doi:10.1016/j.prp.2017.07.011

Cited by 3 publications

(2 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Tumor necrosis factor alpha (TNF-α), Endotoxin, and Interleukin-1β (IL-1β) can reduce TM expression via proteolytic release, internalization, and transcriptional expression [2] . Considering the previous data, local tissue hemostasis including TM may play a role in the pathogenesis of psoriasis [39] .…”

Section: Tm and Psoriasismentioning

confidence: 81%

Thrombomodulin in skin diseases

Aboalkher¹,

El-Sayed

Sayed

et al. 2021

Journal of Recent Advances in Medicine

View full text Add to dashboard Cite

Background: Thrombomodulin (TM) is a glycoprotein presented as a transmembrane molecule on the surface of the cell. It was originally recognized in vascular endothelium. TM is one of the natural anticoagulant mechanisms. TM has also anti-inflammatory functions in addition to its function in hemostasis. TM is an important cofactor that influences various biological conditions. Inflammatory and thrombotic disorders can display changes in TM expression and its partner proteins. On the other hand, in multiple autoimmune inflammatory disorders, several previous studies have recognized TM as a cofactor. TM was also recognized in other types of the cells rather than the vascular endothelium, including the epidermal keratinocytes. However, the function of TM in the skin and its role in the pathogenesis of skin diseases has been investigated in only a few studies.Objective: to highlights the recent findings relevant to the role of TM in the skin and some dermatological diseases including psoriasis.Conclusion: TM has diverse and complex functions other than its role as an anticoagulant protein making it a target in the future for various approaches to the treatment of several inflammatory, proliferative and immune-mediated disorders.

show abstract

Section: Tm and Psoriasismentioning

confidence: 81%

Thrombomodulin in skin diseases

Aboalkher¹,

El-Sayed

Sayed

et al. 2021

Journal of Recent Advances in Medicine

View full text Add to dashboard Cite

show abstract

“…The sections were then incubated with primary antibodies (diluted at 1:200) for 60 min at room temperature, incubated with secondary antibody (not diluted) for 45 min at room temperature, treated with diaminobenzidine color, counterstained with hematoxylin at room temperature for 4 min and tablet sealed. Each step was performed as per the kit manufacturer's instructions (18). The results of ERG IHC were observed by the light microscope (Olympus Corporation).…”

Section: Immunohistochemical Reagents Methods and Judgment Of Resultsmentioning

confidence: 99%

Prognostic value of E‑26 transformation‑specific‑related gene in prostate cancer based on immunohistochemistry analysis

et al. 2023

View full text Add to dashboard Cite

E-26 transformation-specific-related gene (ERG) has been implicated in prostate cancer; however, its prognostic role remains unclear. Therefore, the present study aimed to investigate the association of ERG with the prognosis after radical prostatectomy in patients with prostate cancer. Patient data were collected at the Huadong Hospital, affiliated with Fudan University, between January 2016 and March 2020. ERG protein expression was detected using immunohistochemistry. Independent-sample t-tests and χ 2 tests were used to evaluate prostate cancer prognosis depending on ERG levels. The Kaplan-Meier method was used to estimate biochemical failure-free survival (BFFS) and the log-rank test was used to test the distribution. Prognostic factors were determined using Cox regression analysis. The median patient age was 69 years (range, 47-82 years). The median prostate-specific antigen (PSA) and free-PSA levels before treatment were 9.58 ng/ml (range, 0.003-187.400 ng/ml) and 1.13 ng/ml (range, 0.0059-30.6100 ng/ml), respectively. ERG protein expression was positive in 43 (16.6%) and negative in 216 (83.4%) cases. The median follow-up period and BFFS were 30 and 28 months, respectively. There was a significant difference in biochemical recurrence (P= 0.017) between patients with positive and negative ERG expression. Patients with positive ERG expression had significantly worse BFFS curves compared with those with negative ERG expression (P= 0.0038). In the multivariate Cox regression analysis, positive ERG expression was found to be an independent prognostic factor in patients with prostate cancer who underwent radical prostatectomy (hazard ratio, 4.08; 95% confidence interval, 2.03-8.17; P=0.000074). In conclusion, positive ERG expression is an independent prognostic risk factor for prostate cancer. These findings may be valuable for improvements in the clinical application of ERG immunohistochemistry.

show abstract